Shareholder_NN information_NN Dividends_NNS per_IN ADS_NNPS Share_NNP price_NN The_DT table_NN below_IN sets_NNS out_IN the_DT dividends_NNS per_IN ADS_NNPS paid_VBN in_IN US_NNP dollars_NNS in_IN 2005 2004 2003_CD the_DT last_JJ five_CD years_NNS ,_, translated_VBN into_IN US_NNP dollars_NNS at_IN applicable_JJ exchange_NN rates_NNS ._.
At_IN 1st_CD January_NNP 12.22_CD 12.80_CD 11.92_CD Year_NN US$_$ High_JJ during_IN the_DT year_NN 15.44_CD 12.99_CD 13.90_CD 2005_CD 1.57_CD Low_NNP during_IN the_DT year_NN 11.75_CD 10.42_CD 10.00_CD 2004_CD 1.53_CD At_IN 31st_CD December_NNP 14.69_CD 12.22_CD 12.80_CD 2003_CD 1.39_CD Increase_VBP Decrease_NNP 20_CD %_NN 5_CD %_NN 7_CD %_NN 2002_CD 1.24_CD The_DT table_NN above_IN sets_NNS out_IN the_DT middle_JJ market_NN closing_NN prices_NNS derived_VBN 2001_CD 1.11_CD from_IN the_DT London_NNP Stock_NNP Exchange_NNP Daily_NNP Official_NNP List_NN ._.
The_DT companys_NNS share_VBP price_NN increased_VBN by_IN 20_CD %_NN in_IN 2005_CD from_IN a_DT price_NN of_IN 12.22_CD at_IN 1st_CD Dividend_NN calendar_NN January_NNP 2005_CD to_TO 14.69_CD at_IN 31st_CD December_NNP 2005_CD ._.
This_DT compares_VBZ with_IN Fourth_JJ quarter_NN 2005_CD an_DT increase_NN in_IN the_DT FTSE_NNP 100_CD index_NN of_IN 17_CD %_NN during_IN the_DT year_NN ._.
Ex-dividend_NN date_NN 15th_JJ February_NNP 2006_CD Market_NNP capitalization_NN Record_NNP date_NN 17th_JJ February_NNP 2006_CD The_DT market_NN capitalization_NN ,_, based_VBN on_IN shares_NNS in_IN public_JJ issue_NN ,_, of_IN Payable_JJ 6th_JJ April_NNP 2006_CD GlaxoSmithKline_NNP at_IN 31st_CD December_NNP 2005_CD was_VBD 85_CD billion_CD ._.
At_IN that_DT date_NN GSK_NNP was_VBD the_DT fourth_JJ largest_JJS company_NN by_IN market_NN capitalization_NN on_IN the_DT First_JJ quarter_NN 2006_CD FTSE_NNP index_NN ._.
Ex-dividend_NN date_NN 10th_JJ May_NNP 2006_CD Record_NNP date_NN 12th_JJ May_NNP 2006_CD SmithKline_NNP Beecham_NNP plc_NN Floating_VBG Rate_NNP Unsecured_NNP Payable_NNP 6th_VBZ July_NNP 2006_CD Loan_NNP Stock_NNP 1990_CD 2010_CD The_DT loan_NN stock_NN is_VBZ not_RB listed_VBN on_IN any_DT exchange_NN but_CC holders_NNS may_MD require_VB Second_JJ quarter_NN 2006_CD SmithKline_NNP Beecham_NNP plc_NN to_TO redeem_VB their_PRP$ loan_NN stock_NN at_IN par_NN ,_, i._FW e._FW 1_CD for_IN Ex-dividend_NN date_NN 2nd_JJ August_NNP 2006_CD every_DT 1_CD of_IN loan_NN stock_NN held_VBN ,_, on_IN the_DT first_JJ business_NN day_NN of_IN March_NNP ,_, June_NNP ,_, Record_NNP date_NN 4th_JJ August_NNP 2006_CD September_NNP and_CC December_NNP ._.
Holders_NNS wishing_VBG to_TO redeem_VB all_DT or_CC part_NN of_IN Payable_JJ 5th_JJ October_NNP 2006_CD their_PRP$ loan_NN stock_NN should_MD complete_VB the_DT notice_NN on_IN the_DT back_NN of_IN their_PRP$ loan_NN stock_NN certificate_NN and_CC return_VB it_PRP to_TO the_DT registrar_NN ,_, to_TO arrive_VB at_IN least_JJS 30_CD days_NNS Third_JJ quarter_NN 2006_CD before_IN the_DT relevant_JJ redemption_NN date_NN ._.
Ex-dividend_NN date_NN 1st_CD November_NNP 2006_CD Record_NNP date_NN 3rd_CD November_NNP 2006_CD Taxation_NNP Payable_NNP 4th_JJ January_NNP 2007_CD General_NNP information_NN concerning_VBG the_DT UK_NNP and_CC US_NNP tax_NN effects_NNS of_IN share_NN ownership_NN is_VBZ set_VBN out_RP in_IN `_`` Taxation_NNP information_NN for_IN shareholders_NNS '_POS on_IN Internet_NNP page_NN 186_CD ._.
Information_NN about_IN the_DT company_NN including_VBG details_NNS of_IN the_DT share_NN price_NN is_VBZ available_JJ on_IN GSKs_NNS website_VBP at_IN www_NN ._.
Dividends_NNP Information_NNP made_VBD available_JJ on_IN the_DT website_NN does_VBZ not_RB constitute_VB part_NN GlaxoSmithKline_NNP pays_VBZ dividends_NNS quarterly_RB ._.
Details_NNS of_IN the_DT dividends_NNS of_IN this_DT Annual_JJ Report_NNP ._.
declared_VBN ,_, the_DT amount_NN and_CC the_DT payment_NN dates_NNS are_VBP given_VBN in_IN Note_NN 14_CD ._.
Investor_NNP relations_NNS Dividends_NNPS per_IN share_NN The_DT table_NN below_IN sets_NNS out_IN the_DT dividends_NNS per_IN share_NN paid_VBN in_IN the_DT last_JJ five_CD Investor_NNP Relations_NNPS may_MD be_VB contacted_VBN as_IN follows_VBZ :_: years_NNS ._.
At_IN 24th_JJ February_NNP 2006_CD ,_, the_DT number_NN of_IN holders_NNS of_IN record_NN of_IN shares_NNS in_IN the_DT USA_NNP was_VBD 1,190_CD with_IN holdings_NNS of_IN 1,543,844_CD shares_NNS ,_, and_CC the_DT number_NN of_IN registered_VBN holders_NNS of_IN the_DT ADRs_NNPS was_VBD 41,589_CD with_IN holdings_NNS of_IN 415,217,646_CD ADRs_NNS ._.
Certain_NNP of_IN these_DT shares_NNS and_CC ADRs_NNS were_VBD held_VBN by_IN brokers_NNS or_CC other_JJ nominees_NNS ._.
As_IN a_DT result_NN the_DT number_NN of_IN holders_NNS of_IN record_NN or_CC registered_VBN holders_NNS in_IN the_DT USA_NNP is_VBZ not_RB representative_JJ of_IN the_DT number_NN of_IN beneficial_JJ holders_NNS or_CC of_IN the_DT residence_NN of_IN beneficial_JJ holders_NNS ._.
Control_NN of_IN company_NN As_IN far_RB as_RB is_VBZ known_VBN to_TO the_DT company_NN ,_, it_PRP is_VBZ not_RB directly_RB or_CC indirectly_RB owned_VBN or_CC controlled_VBN by_IN one_CD or_CC more_JJR corporations_NNS or_CC by_IN any_DT government_NN ._.
The_DT company_NN does_VBZ not_RB know_VB of_IN any_DT arrangements_NNS ,_, the_DT operation_NN of_IN which_WDT might_MD result_VB in_IN a_DT change_NN in_IN control_NN of_IN the_DT company_NN ._.
Major_JJ shareholders_NNS have_VBP the_DT same_JJ voting_NN rights_NNS per_IN share_NN as_IN all_DT other_JJ shareholders_NNS ._.
Substantial_JJ shareholdings_NNS At_IN 24th_JJ February_NNP 2006_CD ,_, the_DT company_NN had_VBD received_VBN notification_NN of_IN the_DT following_VBG interests_NNS of_IN 3_CD %_NN or_CC more_JJR in_IN the_DT shares_NNS in_IN issue_NN ,_, excluding_VBG Treasury_NNP shares_NNS :_: BNY_NNP Nominees_NNPS Limited_NNP holds_VBZ 830,443,108_CD shares_NNS representing_VBG 14.26_CD %_NN ._.
These_DT shares_NNS are_VBP held_VBN on_IN behalf_NN of_IN holders_NNS of_IN ADRs_NNS ,_, which_WDT evidence_NN ADSs_NNS ._.
Legal_NNP &_CC General_NNP Investment_NNP Management_NNP Limited_NNP holds_VBZ 212,219,375_CD shares_NNS representing_VBG 3.64_CD %_NN ._.
Barclays_NNP PLC_NNP holds_VBZ 221,114,143_CD shares_NNS representing_VBG 3.80_CD %_NN ._.
As_IN far_RB as_RB is_VBZ known_VBN to_TO the_DT company_NN ,_, no_DT other_JJ person_NN was_VBD the_DT owner_NN of_IN 3_CD %_NN or_CC more_JJR of_IN the_DT shares_NNS in_IN issue_NN ,_, excluding_VBG Treasury_NNP Shares_NNS of_IN the_DT company_NN ._.
Directors_NNS and_CC Officers_NNS The_DT interests_NNS of_IN the_DT Directors_NNS and_CC Officers_NNS of_IN the_DT company_NN ,_, as_IN defined_VBN in_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, in_IN share_NN options_NNS of_IN the_DT company_NN are_VBP given_VBN in_IN the_DT Remuneration_NNP Report_NNP pages_NNS 37_CD to_TO 54_CD ._.
Exchange_NNP controls_NNS and_CC other_JJ limitations_NNS affecting_VBG security_NN holders_NNS There_EX are_VBP currently_RB no_DT UK_NNP laws_NNS ,_, decrees_NNS or_CC regulations_NNS restricting_VBG the_DT import_NN or_CC export_NN of_IN capital_NN or_CC affecting_VBG the_DT remittance_NN of_IN dividends_NNS or_CC other_JJ payments_NNS to_TO holders_NNS of_IN the_DT companys_NNS shares_NNS who_WP are_VBP non-residents_NNS of_IN the_DT UK_NNP ._.
There_EX are_VBP no_DT limitations_NNS relating_VBG only_RB to_TO non-residents_NNS of_IN the_DT UK_NNP under_IN English_NNP law_NN or_CC the_DT companys_NNS Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP on_IN the_DT right_NN to_TO be_VB a_DT holder_NN of_IN ,_, and_CC to_TO vote_VB in_IN respect_NN of_IN ,_, the_DT companys_NNS shares_NNS ._.
Documents_NNS on_IN display_NN The_DT Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP of_IN the_DT company_NN and_CC other_JJ documents_NNS referred_VBD to_TO in_IN this_DT Annual_JJ Report_NNP are_VBP available_JJ for_IN inspection_NN at_IN the_DT Registered_NNP Office_NNP of_IN the_DT company_NN ._.
Publications_NNP In_IN late_JJ March_NNP 2006_CD GSK_NNP will_MD publish_VB on_IN the_DT website_NN its_PRP$ Corporate_JJ Responsibility_NN Report_NNP covering_VBG performance_NN in_IN areas_NNS including_VBG community_NN investment_NN ,_, ethics_NNS and_CC integrity_NN ,_, access_NN to_TO medicines_NNS ,_, R&D_NNP and_CC environment_NN health_NN and_CC safety_NN ._.
GSK_NNP Annual_JJ Report_NNP 2005_CD 183_CD INVESTOR_NN INFORMATION_NNP Shareholder_NN information_NN continued_VBD Nature_NNP of_IN trading_VBG market_NN Annual_JJ General_NNP Meeting_VBG 2006_CD The_DT Ordinary_NNP Shares_NNP of_IN the_DT company_NN were_VBD listed_VBN on_IN the_DT London_NNP Stock_NNP The_NNP Queen_NNP Elizabeth_NNP II_NNP Conference_NNP Centre_NNP ,_, 17th_JJ May_NNP 2006_CD Exchange_NNP on_IN 27th_JJ December_NNP 2000_CD ._.
The_DT shares_NNS were_VBD also_RB listed_VBN on_IN the_DT Broad_NNP Sanctuary_NNP ,_, Westminster_NNP ,_, New_NNP York_NNP Stock_NNP Exchange_NNP NYSE_NNP in_IN the_DT form_NN of_IN American_JJ Depositary_NNP London_NNP SW1P_NNP 3EE_NNP Shares_NNP ADSs_NNPS from_IN the_DT same_JJ date_NN ._.
The_DT Annual_JJ General_NNP Meeting_VBG is_VBZ the_DT company_NN 's_POS principal_JJ forum_NN for_IN The_DT following_VBG tables_NNS set_VBN out_RP ,_, for_IN the_DT periods_NNS indicated_VBD ,_, the_DT high_JJ and_CC communication_NN with_IN private_JJ shareholders_NNS ._.
In_IN addition_NN to_TO the_DT formal_JJ low_JJ middle_JJ market_NN closing_VBG quotations_NNS in_IN pence_NN for_IN the_DT shares_NNS on_IN the_DT business_NN there_EX will_MD be_VB a_DT presentation_NN by_IN the_DT Chief_NNP Executive_NNP Officer_NNP on_IN London_NNP Stock_NNP Exchange_NNP ,_, and_CC the_DT high_JJ and_CC low_JJ last_JJ reported_VBD sales_NNS the_DT performance_NN of_IN the_DT Group_NNP and_CC its_PRP$ future_JJ development_NN ._.
There_EX will_MD prices_NNS in_IN US_NNP dollars_NNS for_IN the_DT ADSs_NNS on_IN the_DT NYSE_NNP ._.
be_VB opportunity_NN for_IN questions_NNS to_TO the_DT Board_NNP ,_, and_CC the_DT Chairmen_NNPS of_IN the_DT Board_NNP 's_POS committees_NNS will_MD take_VB questions_NNS on_IN matters_NNS relating_VBG to_TO those_DT GlaxoSmithKline_NNP Pence_NNP per_IN share_NN committees_NNS ._.
High_NNP Low_NNP Investors_NNPS holding_VBG shares_NNS in_IN the_DT company_NN through_IN a_DT nominee_NN service_NN Quarter_NN ended_VBD 31st_CD March_NNP 2006 1500 1424_CD should_MD arrange_VB with_IN that_DT nominee_NN service_NN to_TO be_VB appointed_VBN as_IN a_DT February_NNP 2006 1500 1434_CD corporate_JJ representative_NN or_CC proxy_NN in_IN respect_NN of_IN their_PRP$ shareholding_NN in_IN January_NNP 2006 1496 1424_CD order_NN to_TO attend_VB and_CC vote_VB at_IN the_DT meeting_NN ._.
December_NNP 2005 1483 1434_CD November_NNP 2005 1544 1429_CD ADR_NNP holders_NNS wishing_VBG to_TO attend_VB the_DT meeting_NN must_MD obtain_VB a_DT proxy_NN from_IN October_NNP 2005 1473 1395_CD The_NNP Bank_NNP of_IN New_NNP York_NNP which_WDT will_MD enable_VB them_PRP to_TO attend_VB the_DT meeting_NN September_NNP 2005 1442 1343_CD and_CC vote_VB on_IN the_DT business_NN to_TO be_VB transacted_VBN ._.
ADR_NNP holders_NNS may_MD instruct_VB Quarter_NN ended_VBD 31st_CD December_NNP 2005 1544 1395_CD The_NNP Bank_NNP of_IN New_NNP York_NNP as_IN to_TO the_DT way_NN in_IN which_WDT the_DT shares_NNS represented_VBD Quarter_NN ended_VBD 30th_JJ September_NNP 2005 1442 1308_CD by_IN their_PRP$ ADRs_NNS should_MD be_VB voted_VBN by_IN completing_VBG and_CC returning_VBG the_DT voting_NN Quarter_NN ended_VBD 30th_JJ June_NNP 2005 1377 1201_CD card_NN provided_VBN by_IN the_DT bank_NN in_IN accordance_NN with_IN the_DT instructions_NNS given_VBN ._.
Quarter_NN ended_VBD 31st_CD March_NNP 2005 1318 1175_CD Quarter_NN ended_VBD 31st_CD December_NNP 2004 1222 1101_CD Financial_NNP reporting_VBG Quarter_NN ended_VBD 30th_JJ September_NNP 2004 1209 1042_CD Financial_NNP reporting_VBG calendar_NN 2006_CD Quarter_NN ended_VBD 30th_JJ June_NNP 2004 1201 1067_CD Announcement_NN of_IN 1st_CD Quarter_NN Results_NNS April_NNP 2006_CD Quarter_NN ended_VBD 31st_CD March_NNP 2004 1299 1060_CD Year_NN ended_VBD 31st_CD December_NNP 2003 1390 1000_CD Announcement_NN of_IN 2nd_CD Quarter_NN Results_NNS July_NNP 2006_CD Year_NN ended_VBD 31st_CD December_NNP 2002 1780 1057_CD Announcement_NN of_IN 3rd_CD Quarter_NN Results_NNS October_NNP 2006_CD Year_NN ended_VBD 31st_CD December_NNP 2001 2032 1626_CD Preliminary_JJ Announcement_NN of_IN Annual_JJ Results_NNS February_NNP 2007_CD Publication_NN of_IN Annual_JJ Report_NNP Review_NNP March_NNP 2007_CD US_NNP dollars_NNS per_IN ADS_NNPS High_NNP Low_NNP Results_NNS Announcements_NNP Quarter_NN ended_VBD 31st_CD March_NNP 2006_CD 52.77_CD 50.15_CD Results_NNS Announcements_NNS are_VBP issued_VBN to_TO the_DT London_NNP Stock_NNP Exchange_NNP February_NNP 2006_CD 52.15_CD 50.31_CD and_CC are_VBP available_JJ on_IN its_PRP$ news_NN service_NN ._.
Shortly_RB afterwards_RB ,_, they_PRP are_VBP January_NNP 2006_CD 52.77_CD 50.15_CD issued_VBN to_TO the_DT media_NNS ,_, are_VBP made_VBN available_JJ on_IN the_DT website_NN and_CC sent_VBN to_TO December_NNP 2005_CD 51.97_CD 50.17_CD the_DT US_NNP Securities_NNPS and_CC Exchange_NNP Commission_NNP and_CC the_DT NYSE_NNP ._.
November_NNP 2005_CD 53.53_CD 49.16_CD October_NNP 2005_CD 52.39_CD 49.36_CD Financial_NNP reports_NNS September_NNP 2005_CD 51.28_CD 49.45_CD The_DT company_NN publishes_VBZ an_DT Annual_JJ Report_NNP and_CC ,_, for_IN the_DT investor_NN not_RB Quarter_NN ended_VBD 31st_CD December_NNP 2005_CD 53.53_CD 49.16_CD needing_VBG the_DT full_JJ detail_NN of_IN the_DT Report_NNP ,_, an_DT Annual_JJ Review_NNP ._.
These_DT are_VBP Quarter_NN ended_VBD 30th_JJ September_NNP 2005_CD 51.28_CD 46.47_CD available_JJ from_IN the_DT date_NN of_IN publication_NN on_IN the_DT website_NN ._.
Quarter_NN ended_VBD 30th_JJ June_NNP 2005_CD 51.40_CD 45.19_CD The_DT Annual_JJ Review_NNP is_VBZ sent_VBN to_TO all_DT shareholders_NNS on_IN the_DT date_NN of_IN Quarter_NN ended_VBD 31st_CD March_NNP 2005_CD 50.50_CD 44.48_CD publication_NN ._.
Shareholders_NNS may_MD also_RB elect_VB to_TO receive_VB the_DT Annual_JJ Report_NNP Quarter_NN ended_VBD 31st_CD December_NNP 2004_CD 47.50_CD 41.15_CD by_IN writing_VBG to_TO the_DT companys_NNS registrars_NNS ._.
Alternatively_RB shareholders_NNS may_MD Quarter_NN ended_VBD 30th_JJ September_NNP 2004_CD 43.84_CD 39.04_CD elect_VBP to_TO receive_VB notification_NN by_IN email_NN of_IN the_DT publication_NN of_IN financial_JJ Quarter_NN ended_VBD 30th_JJ June_NNP 2004_CD 43.50_CD 39.44_CD reports_NNS by_IN registering_VBG on_IN www_NN ._.
Quarter_NN ended_VBD 31st_CD March_NNP 2004_CD 46.93_CD 39.38_CD Year_NN ended_VBD 31st_CD December_NNP 2003_CD 47.40_CD 32.75_CD Copies_NNS of_IN previous_JJ financial_JJ reports_NNS are_VBP available_JJ on_IN the_DT website_NN ._.
Year_NN ended_VBD 31st_CD December_NNP 2002_CD 50.87_CD 32.86_CD Printed_NNP copies_NNS can_MD be_VB obtained_VBN from_IN the_DT registrar_NN in_IN the_DT UK_NNP and_CC from_IN Year_NN ended_VBD 31st_CD December_NNP 2001_CD 57.76_CD 48.80_CD the_DT Customer_NN Response_NNP Center_NNP in_IN the_DT USA_NNP ._.
to_TO 24th_JJ February_NNP 2006_CD GSK_NNP Annual_JJ Report_NNP 2005_CD 184_CD INVESTOR_NN INFORMATION_NNP Shareholder_NN information_NN continued_VBD Ordinary_JJ shares_NNS The_DT companys_NNS shares_NNS are_VBP listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP ._.
Registrar_NNP The_NNP companys_VBZ registrars_NNS are_VBP :_: Lloyds_NNP TSB_NNP Registrars_NNPS The_DT Causeway_NNP ,_, Worthing_NNP ,_, West_NNP Sussex_NNP BN99_NNP 6DA_NNP www_NN ._.
co._FW uk_FW Tel_NNP :_: 0870 600 3991_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP The_DT registrars_NNS also_RB provide_VBP the_DT following_JJ services_NNS :_: GlaxoSmithKline_NNP Investment_NNP Plan_NNP GlaxoSmithKline_NNP Individual_NNP Savings_NNP Account_NNP GlaxoSmithKline_NNP Corporate_NNP Sponsored_NNP Nominee_NNP Shareview_NNP service_NN Shareview_NNP dealing_VBG service_NN Share_NN dealing_VBG service_NN Hoare_NNP Govett_NNP operate_VBP a_DT postal_JJ dealing_VBG service_NN in_IN the_DT companys_NNS ordinary_JJ shares_NNS ._.
It_PRP enables_VBZ investors_NNS to_TO buy_VB or_CC sell_VB shares_NNS at_IN competitive_JJ commission_NN charges_NNS ._.
Further_JJ details_NNS may_MD be_VB obtained_VBN by_IN telephoning_VBG 44_CD 0_CD 207 661 6555_NNS ._.
Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP corporate_JJ PEPs_NNS The_DT Share_NN Centre_NNP Limited_NNP Oxford_NNP House_NNP ,_, Oxford_NNP Road_NNP ,_, Aylesbury_NNP ,_, Bucks_NNP HP21_NNP 8SZ_NNP Tel_NNP :_: 44_CD 0_CD 1296 414141_CD The_DT provision_NN of_IN the_DT details_NNS above_IN is_VBZ not_RB intended_VBN to_TO be_VB an_DT invitation_NN or_CC inducement_NN to_TO engage_VB in_IN an_DT investment_NN activity_NN ._.
Advice_NNP on_IN share_NN dealing_VBG should_MD be_VB obtained_VBN from_IN a_DT stockbroker_NN or_CC independent_JJ financial_JJ adviser_NN ._.
American_JJ Depositary_NNP Shares_NNP The_NNP companys_VBZ shares_NNS are_VBP listed_VBN on_IN the_DT NYSE_NNP in_IN the_DT form_NN of_IN American_JJ Depositary_NNP Shares_NNP and_CC these_DT are_VBP evidenced_VBN by_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS ,_, each_DT one_CD of_IN which_WDT represents_VBZ two_CD ordinary_JJ shares_NNS ._.
In_IN general_JJ ,_, the_DT NYSEs_NNP rules_NNS permit_VBP the_DT company_NN to_TO follow_VB UK_NNP corporate_JJ governance_NN practices_NNS instead_RB of_IN those_DT that_WDT apply_VBP in_IN the_DT USA_NNP ,_, provided_VBD that_IN the_DT company_NN explains_VBZ any_DT significant_JJ variations_NNS ._.
This_DT explanation_NN is_VBZ provided_VBN on_IN the_DT companys_NNS website_VBP ._.
ADR_NNP program_NN administrator_NN The_DT ADR_NNP program_NN is_VBZ administered_VBN by_IN :_: The_DT Bank_NNP of_IN New_NNP York_NNP Shareholder_NN Relations_NNP PO_NNP Box_NNP 11258_CD ,_, Church_NNP Street_NNP Station_NNP New_NNP York_NNP NY_NNP 10286-1258_CD www_NN ._.
com_NN Tel_NNP :_: 1_CD 877 353 1154_CD toll_NN free_JJ Tel_NNP :_: 1_CD 212 815 3700_CD outside_IN the_DT USA_NNP Customer_NN Response_NNP Center_NNP Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ The_DT administrators_NNS also_RB provide_VBP Global_JJ BuyDIRECT_NNP ,_, a_DT direct_JJ ADS_NNPS purchase_NN sale_NN and_CC dividend_NN reinvestment_NN plan_NN for_IN ADR_NNP holders_NNS ._.
GSK_NNP Annual_JJ Report_NNP 2005_CD 185_CD INVESTOR_NN INFORMATION_NN
